Huaren PharmaceuticalReleased on the evening of January 9PerformanceForecast, it is expected to belong to a listed company in 2021shareholderofNet profit125 million to 150 million yuan, an increase of 32.1% to 58.52% year-on-year; the same period last year, due to the epidemic, the company’s pharmaceutical business was affected to a certain extent. During the reporting period, as the domestic epidemic was effectively controlled, the company continued to integrate and improve sales channels, actively explored incremental markets, strengthened market access, and actively responded to the national, provincial, and municipal three-level centralized procurement policies. There was an increase in the same period last year. During the reporting period, the company actively promoted the layout of the entire pharmaceutical and health industry chain.Pharmaceutical businessThe segment business grew steadily and contributed part of the profit. In November 2020, the company acquired 100% equity of Guangxi Yuyuan Pharmaceutical Co., Ltd. and Pubei Xinke Pharmaceutical Packaging Co., Ltd., which were included in the consolidated statement in November 2020, and contributed part of the profit during the reporting period.
Huaren PharmaceuticalThe president and chairman of the board are Yang Xiaodong, male, 54 years old, with a doctorate degree.
(Reporter Cai Ding)
(Source: Daily Economic News)
Article source: Daily Economic News
Editor in charge: 6
Original title: Pre-increase! Huaren Pharmaceutical: The net profit for 2021 is expected to be 125 million to 150 million yuan, a year-on-year increase of 32.1% to 58.52%
Solemnly declare: The purpose of this information is to spread more information, and it has nothing to do with this stand.
report
Scan the QR code to follow
Oriental Wealth Official Website WeChat
.